Sentry Investment Management LLC Has $380,000 Position in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Sentry Investment Management LLC increased its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 215.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,718 shares of the company’s stock after buying an additional 3,223 shares during the quarter. Sentry Investment Management LLC’s holdings in PROCEPT BioRobotics were worth $380,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Raleigh Capital Management Inc. purchased a new position in PROCEPT BioRobotics during the 4th quarter valued at about $32,000. IFP Advisors Inc purchased a new position in PROCEPT BioRobotics during the fourth quarter valued at approximately $58,000. Arcadia Investment Management Corp MI acquired a new position in PROCEPT BioRobotics in the 4th quarter valued at approximately $64,000. Wilmington Savings Fund Society FSB acquired a new stake in shares of PROCEPT BioRobotics during the 3rd quarter valued at $64,000. Finally, Canton Hathaway LLC purchased a new position in shares of PROCEPT BioRobotics during the 3rd quarter valued at $66,000. 89.46% of the stock is owned by institutional investors and hedge funds.

PROCEPT BioRobotics Stock Down 3.7 %

PRCT opened at $62.71 on Wednesday. The firm has a market cap of $3.27 billion, a P/E ratio of -32.16 and a beta of 1.03. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The business has a 50 day moving average price of $75.53 and a 200 day moving average price of $80.02. PROCEPT BioRobotics Co. has a twelve month low of $45.20 and a twelve month high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The firm had revenue of $68.24 million during the quarter, compared to analyst estimates of $66.79 million. Research analysts forecast that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on PRCT shares. Morgan Stanley began coverage on PROCEPT BioRobotics in a research report on Monday, December 2nd. They set an “overweight” rating and a $105.00 price objective for the company. Truist Financial reissued a “buy” rating and issued a $105.00 price target (up previously from $95.00) on shares of PROCEPT BioRobotics in a research note on Wednesday, October 30th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $112.00 price objective on shares of PROCEPT BioRobotics in a research report on Tuesday, December 3rd. Finally, Jefferies Financial Group assumed coverage on shares of PROCEPT BioRobotics in a research report on Thursday, November 14th. They issued a “hold” rating and a $95.00 target price for the company. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, PROCEPT BioRobotics has an average rating of “Moderate Buy” and an average target price of $97.86.

Insider Buying and Selling at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 26,423 shares of PROCEPT BioRobotics stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $97.22, for a total value of $2,568,844.06. Following the transaction, the chief executive officer now directly owns 152,762 shares of the company’s stock, valued at $14,851,521.64. The trade was a 14.75 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Alaleh Nouri sold 28,092 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $97.13, for a total value of $2,728,575.96. Following the completion of the sale, the executive vice president now directly owns 52,472 shares of the company’s stock, valued at $5,096,605.36. This represents a 34.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).